Immuneering (IMRX) Cash from Financing Activities (2020 - 2026)
Immuneering (IMRX) recorded quarterly Cash from Financing Activities of $180760.0 in Q1 2026, up 150.56% quarter-over-quarter from -$357523.0 in Q4 2025, and down 98.69% on a YoY basis from $13.8 million in Q1 2025.
Immuneering (IMRX) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Immuneering's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $180760.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 98.69% year-over-year to $180760.0; the TTM figure through Mar 2026 stood at $213.0 million (up 1074.32% YoY), while the FY2025 annual figure was $226.6 million, up 4172.32% from the prior year.
- Cash from Financing Activities was $180760.0 for Q1 2026 at Immuneering, up from -$357523.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $213.2 million in Q3 2025 to a low of -$357523.0 in Q4 2025.
- Historically, Cash from Financing Activities has averaged $16.3 million across 5 years, with a median of $104272.0 in 2022.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities plunged 2556.14% in 2022, then surged 101297.86% in 2023.
- A 5-year view of Cash from Financing Activities shows it stood at -$184677.0 in 2022, then jumped by 104.24% to $7835.0 in 2023, then sank by 623.14% to -$40988.0 in 2024, then plunged by 772.26% to -$357523.0 in 2025, then jumped by 150.56% to $180760.0 in 2026.
- The last three Cash from Financing Activities figures came in at $180760.0 (Q1 2026), -$357523.0 (Q4 2025), and $213.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 85,464.43 |
| 10 | Immuneering | 255.40 Mn | 255.40 Mn | - | 180,760.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 180,760.00 |
| Mar 31, 2026 | 180,760.00 |
| Dec 31, 2025 | -357,523.00 |
| Dec 31, 2025 | -357,523.00 |
| Sep 30, 2025 | 213.19 Mn |
| Sep 30, 2025 | 213.19 Mn |
| Jun 30, 2025 | -61,958.00 |
| Jun 30, 2025 | -61,958.00 |
| Mar 31, 2025 | 13.81 Mn |
| Mar 31, 2025 | 13.81 Mn |
| Dec 31, 2024 | -40,988.00 |
| Dec 31, 2024 | -40,988.00 |
| Sep 30, 2024 | 4.36 Mn |
| Sep 30, 2024 | 4.36 Mn |
| Mar 31, 2024 | 979,923.00 |
| Mar 31, 2024 | 979,923.00 |
| Dec 31, 2023 | 7,835.00 |
| Dec 31, 2023 | 7,835.00 |
| Sep 30, 2023 | 21,448.00 |
| Sep 30, 2023 | 21,448.00 |